Fiber Feeds Bacteria to Control Type 2 Diabetes Mellitus

Investigators pit high-fiber diet against standard diet for glycemic control

By Mark Davis, ND, and Jacob Schor, ND, FABNO

Printer Friendly PagePrinter Friendly Page



This paper is part of NMJ's 2018 Microbiome Special Issue. Download the full issue here.


Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151-1156.


To determine effects of a high-fiber diet on the gut microbiome and glucose regulation in individuals with established type 2 diabetes.


Randomized, open-label, parallel-group clinical trial


Forty-three patients with clinically diagnosed type 2 diabetes mellitus were randomized to either an intervention group (n=27) or the control group (n=16).

Study Medication and Dosage

The experimental group received a high-fiber diet of fresh vegetables, fruits, and nuts, supplemented with a gruel (which included whole grains, beans, peanuts, lotus seed, and yam), bitter melon, and prebiotics. The control group consumed an isocaloric diet based on Chinese Diabetes Society guidelines.

Both groups took the antidiabetic agent acarbose (an amylase inhibitor) and discontinued any previously used glycemic control medications. Acarbose transforms starch into fiber by reducing digestion and making it available as a fermentable carbohydrate to bacteria in the colon. The experimental group had a much higher intake of dietary fiber but daily energy and macronutrient intake was similar between groups.

To determine that interactions between the gut microbiota and the fiber were responsible for any observed changes in function, the gut microbiota from before and after the interventions were transplanted into germ-free mice. These mice ended up with gut biomes that more resembled the transplanted biome of the donor than they resembled each other.

Outcome Measures

Hemoglobin A1c (HbA1c) was the primary outcome measure. Additional outcomes included proportion of participants who achieved glycemic control, fecal short chain fatty acid (SCFA) levels, postprandial glucose, fasting blood glucose, lipid profiles, and other standard metabolic markers.

Key Findings

Increasing fermentable fiber by blocking carbohydrate digestion via the amylase inhibitor acarbose improved markers of type 2 diabetes in both groups, but the high-fiber group did significantly better. Hemoglobin A1c decreased in both groups but more so in the high-fiber group. Reduction in HbA1c was greater in the high-fiber group from 4 weeks onward. A greater portion of patients in the high-fiber group reached adequate glycemic control (HbA1c<7%) compared to the standard-diet group (89% vs 50%). The high-fiber group lost more weight and had better lipid profiles. Improvements came faster and were greater in patients who consumed a high-fiber diet in addition to the enzyme inhibitor.

Germ-free mice transplanted with post-intervention microbiota derived from either patient group did better, showing better metabolic health parameters than mice transplanted with pre-intervention microbiota. Mice transplanted with microbiota obtained post-intervention from the high-fiber group did the best, having the lowest fasting and postprandial blood glucose levels of all mice, mirroring the results in the human patient group.

Metagenomic sequencing was performed on 172 fecal samples collected at 4 time points (days 0, 28, 56, and 84), which led to a catalog of 4,893,833 nonredundant microbial genes. Both patient groups had a reduction in gene richness (the number of genes identified per sample) from day 0 to day 28, along with significant clinical improvements, with no further changes afterward.

These last data challenge the current notion that greater overall diversity implies better health. However, gene richness tended to be higher in the high-fiber group than in the normal diet group after day 28, and this trend was associated with better clinical outcomes in the intervention group.

We already know that high-fiber diets help control diabetes, but we have generally thought this benefit was because higher fiber would lower the glycemic index of carbohydrates.

The high-fiber diet favored the growth of bacteria that produce SCFAs, especially bacteria that produce butyric acid. This increase in acid production significantly lowered gut pH in the high-fiber group. Fifteen bacterial strains were significantly promoted by the high-fiber diet, and 47 strains were significantly reduced. This response was clearly strain-specific; for example, of the 6 strains of Faecalibacterium prausnitzii identified, only 1 strain was significantly promoted by the high-fiber diet. The 15 strains that were promoted were all significantly associated with increased SCFA production, which was inversely correlated with HbA1c.

Practice Implications

This paper further demonstrates that human intestinal microbiota affect blood sugar control. This study suggests that we can improve glycemic control by shifting bacterial populations in the intestinal microbiome. We already know that high-fiber diets help control diabetes, but we have generally thought this benefit was because higher fiber would lower the glycemic index of carbohydrates.1 We have repeated this idea for years even as we began to appreciate that there is little difference in glycemic index between whole grain and white flour products. We can now imagine that the difference in action was that the whole-grain versions provided more fermentable carbohydrates and shifted gut microbiota.

Acarbose is available in the United States and Canada by prescription only but rarely used. In China it is the most common prescription employed for treating early type 2 diabetes, the same indication used in the United States for which we might prescribe metformin.2 A 2014 Chinese study that compared acarbose against metformin showed that both agents decreased HbA1c levels to similar degrees and were equally effective in controlling the disease.3 Metformin also changes the gut microbiota,4 increasing levels of Akkermansia.5 Diabetes is now considered a disease of the gut microbiota.6,7 The botanical extract berberine, which we have often used clinically to replace metformin, also shifts the gut biome in a similar manner as metformin.8

We should note that pharmaceutical companies are experimenting with combining metformin and acarbose together in a single tablet.9

The present study suggests a benefit from inhibiting amylase enzyme action. In this study acarbose was used to block starch digestion. A number of fruits have a similar action. If we were willing to anthropomorphize fruits, we could see how they would prefer any of their consumers to get diarrhea. Such digestive upset increases the odds of the fruit seeds’ dispersal in the vicinity and provides an evolutionary advantage. Thus many fruits contain chemicals that act as amylase inhibitors, including baobab fruit,10 persimmon,11 mango,12 pomegranate,13 a range of anthocyanin-containing berries such as cherries,14 and, in general, polyphenols.15

This study provides a mechanistic explanation for why a diet high in vegetables, which provide fiber, and fruits, which may have anti-amylase action, is useful in treating type 2 diabetes: the gut biome shifts to increase SCFA production. Diabetics are often cautioned against eating fruit, but this advice may actually be counterproductive; in fact, sugar-sweetened fruit juices are significantly associated with the risk of developing type 2 diabetes, but whole fruits16 and 100% fruit juices17 are not. It may eventually prove useful to know the relative amylase inhibitory action and prebiotic content of various types of fruit. A number of classic antidiabetes botanicals are also amylase inhibitors, including Ocimum basilicum (basil)18 and mango.19

In 2013, Schor reviewed a study in this journal20 that suggested various berry jams lower glycemic impact of the bread they are eaten with. In the light of this present study, that earlier information makes better sense. The berry concentrates may have acted as anti-amylose agents, similar to acarbose, while providing fiber content. (Might we suggest toast, jam, and berberine as a possible breakfast for diabetics?)

This study’s results suggest that it may someday be possible to create a probiotic supplement that, taken in combination with a high-fiber diet, may have a significant effect on improving glycemic control. Our only evidence using direct microbial transplantation in humans is a study from 2012 that used fecal microbial transplant (FMT) from healthy, lean donors for men with metabolic syndrome. The men experienced temporary increases in peripheral insulin sensitivity, with a trend toward improved hepatic insulin resistance.21 These changes were related to fecal microbial diversity and increases in SCFAs.22

These data should also prompt us to rethink resistant starches and how they affect diabetes. In the past we thought their benefit was secondary to low glycemic index. Instead their benefit may be in reaching the colon and increasing SCFA production.

About the Authors

Mark Davis, ND, is an internationally known expert on inflammatory bowel disease (IBD), fecal microbiota transplantation, and helminthic therapy. He sees patients at the IBD Specialty Center in Silver Spring, Maryland, and via telehealth for Californians at He's also licensed to practice in Oregon and the District of Columbia. Davis is full-time faculty at Maryland University of Integrative Health and serves on the board of directors of the Gastroenterology Association of Naturopathic Physicians and the Fecal Transplant Foundation. He consults with groups setting up FMT stool banks and programs all over the world. He's a 2011 graduate of National University of Natural Medicine.

Jacob Schor ND, FABNO, is a graduate of National College of Naturopathic Medicine, Portland, Oregon, and now practices in Denver, Colorado. He served as president to the Colorado Association of Naturopathic Physicians and is on the board of directors of the Oncology Association of Naturopathic Physicians. He is recognized as a fellow by the American Board of Naturopathic Oncology. He serves on the editorial board for the International Journal of Naturopathic Medicine, Naturopathic Doctor News and Review (NDNR), and Integrative Medicine: A Clinician's Journal. In 2008, he was awarded the Vis Award by the American Association of Naturopathic Physicians. His writing appears regularly in NDNR, the Townsend Letter, and Natural Medicine Journal, where he is the Abstracts & Commentary editor.


  1. Anderson JW, Randles KM, Kendall CW, Jenkins DJ. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr. 2004;23(1):5-17.
  2. He K, Shi JC, Mao XM. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag. 2014;10:505-511.
  3. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014;2(1):46-55.
  4. Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol. 2014;80(19):5935-5943.
  5. Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727-735.
  6. Harsch IA, Konturek PC. The role of gut microbiota in obesity and type 2 and type 1 diabetes mellitus: new insights into "old" diseases. Med Sci (Basel). 2018;6(2). pii: E32.
  7. Rodriguez J, Hiel S, Delzenne NM. Metformin: old friend, new ways of action-implication of the gut microbiome? Curr Opin Clin Nutr Metab Care. 2018;21(4):294-301.
  8. Zhang X, Zhao Y, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 2015;5:14405.
  9. Tiwari R, Gupta A, Joshi M, Tiwari G. Bilayer tablet formulation of metformin HCl and acarbose: a novel approach to control diabetes. PDA J Pharm Sci Technol. 2014;68(2):138-152.
  10. Coe SA, Clegg M, Armengol M, Ryan L. The polyphenol-rich baobab fruit (Adansonia digitata L.) reduces starch digestion and glycemic response in humans. Nutr Res. 2013;33(11):888-896.
  11. Li K, Yao F, Du J, Deng X, Li C. Persimmon tannin decreased the glycemic response through decreasing the digestibility of starch and inhibiting α-amylase, α-glucosidase, and intestinal glucose uptake. J Agric Food Chem. 2018;66(7):1629-1637.
  12. Pluschke AM, Williams BA, Zhang D, Gidley MJ. Dietary pectin and mango pulp effects on small intestinal enzyme activity levels and macronutrient digestion in grower pigs. Food Funct. 2018;9(2):991-999.
  13. Kerimi A, Nyambe-Silavwe, Gauer JS, Tomás-Barberán FA, Williamson G. Pomegranate juice, but not an extract, confers a lower glycemic response on a high-glycemic index food: randomized, crossover, controlled trials in healthy subjects. Am J Clin Nutr. 2017;106(6):1384-1393.
  14. Homoki JR, Nemes A, Fazekas E, et al. Anthocyanin composition, antioxidant efficiency, and α-amylase inhibitor activity of different Hungarian sour cherry varieties (Prunus cerasus L.). Food Chem. 2016;194:222-229.
  15. Xiao J, Ni X, Kai G, Chen X. A review on structure-activity relationship of dietary polyphenols inhibiting α-amylase. Crit Rev Food Sci Nutr. 2013;53(5):497-506.
  16. Li M, Fan Y, Zhang X, Hou W, Tang Z. Fruit and vegetable intake and risk of type 2 diabetes mellitus: meta-analysis of prospective cohort studies. BMJ Open. 2014;4(11):e005497.
  17. Xi B, Li S, Liu Z, et al. Intake of fruit juice and incidence of type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2014;9(3):e93471.
  18. Ezeani C, Ezenyi I, Okoye T, Okoli C. Ocimum basilicum extract exhibits antidiabetic effects via inhibition of hepatic glucose mobilization and carbohydrate metabolizing enzymes. J Intercult Ethnopharmacol. 2017;6(1):22-28.
  19. Gondi M, Prasada Rao UJ. Ethanol extract of mango (Mangifera indica L.) peel inhibits α-amylase and α-glucosidase activities, and ameliorates diabetes related biochemical parameters in streptozotocin (STZ)-induced diabetic rats. J Food Sci Technol. 2015;52(12):7883-7893.
  20. Schor J. Berries improve glycemic response to bread or sugar. Natural Medicine Journal. 2013;5(10).
  21. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-916.
  22. Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26(4):611-619.